A review on oxaliplatin-induced peripheral nerve damage

Cancer Treatment Reviews

Volumn 34, Issue 4, 2008, Pages 368-377

  Argyriou, Andreas A ^a   Polychronopoulos, Panagiotis ^a   Iconomou, Gregoris ^b   Chroni, Elisabeth ^a   Kalofonos, Haralabos P ^b  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

Diagnosis; Incidence; Neuroprotection; Oxaliplatin; Peripheral neuropathy

Indexed keywords

AMIFOSTINE; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; ANTIOXIDANT; CALCIUM; CALCIUM ION; CARBAMAZEPINE; FLUOROURACIL; FOLINIC ACID; GABAPENTIN; GLUCONATE CALCIUM; GLUTAMINE; GLUTATHIONE; MAGNESIUM; MAGNESIUM SULFATE; NEUROPROTECTIVE AGENT; NEUROTROPHIC FACTOR; OXALIPLATIN; OXCARBAZEPINE; PLACEBO; PLATINUM DERIVATIVE; THIOCTIC ACID; THIOL; TOPIRAMATE; VENLAFAXINE; VOLTAGE GATED SODIUM CHANNEL; XALIPRODEN;

ANTINEOPLASTIC ACTIVITY; AXOPLASM; CELL METABOLISM; CLINICAL EXAMINATION; CLINICAL TRIAL; COLORECTAL CANCER; DRUG INFUSION; HUMAN; INCIDENCE; LOW DRUG DOSE; MEDICAL RESEARCH; NERVE CELL; NERVE CONDUCTION; NEUROLOGIC EXAMINATION; PATHOGENESIS; PERIPHERAL NERVE INJURY; PERIPHERAL NEUROPATHY; QUANTITATIVE ANALYSIS; REVIEW; RISK FACTOR; SOLID TUMOR; SPINAL GANGLION;

GANGLIA, SPINAL; HUMANS; INCIDENCE; NEUROPROTECTIVE AGENTS; ORGANOPLATINUM COMPOUNDS; PERIPHERAL NERVOUS SYSTEM DISEASES; RISK FACTORS; WITHHOLDING TREATMENT;

EID: 43949145933     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2008.01.003     Document Type: Review

References (84)

1. Brabec V., and Kasparkova J. Modifications of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs. Drug Resist Updat 8 3 (2005) 131-146
2. Bécouarn Y., Agostini C., Trufflandier N., and Boulanger V. Oxaliplatin: available data in non-colorectal gastrointestinal malignancies. Crit Rev Oncol Hematol 40 3 (2001) 265-272
3. Kim G.P., and Erlichman C. Oxaliplatin in the treatment of colorectal cancer. Expert Opin Drug Metab Toxicol 3 2 (2007) 281-294
4. Goldberg R.M. Advances in the treatment of metastatic colorectal cancer. Oncologist 10 Suppl 3 (2005) 40-48
5. Hartmann J.T., and Lipp H.P. Toxicity of platinum compounds. Expert Opin Pharmacother 4 6 (2003) 889-901
6. Ocean A.J., and Vahdat L.T. Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. Support Care Cancer 12 9 (2004) 619-625
7. Pasetto L.M., D'Andrea M.R., Rossi E., and Monfardini S. Oxaliplatin-related neurotoxicity: how and why?. Crit Rev Oncol Hematol 59 2 (2006) 159-168
8. Quasthoff S., and Hartung H.P. Chemotherapy-induced peripheral neuropathy. J Neurol 249 1 (2002) 9-17
9. Markman M. Toxicities of the platinum antineoplastic agents. Expert Opin Drug Saf 2 6 (2003) 597-607
10. Cersosimo R.J. Oxaliplatin-associated neuropathy: a review. Ann Pharmacother 39 1 (2005) 128-135
11. Newsom-Davis J. The emerging diversity of neuromuscular junction disorders. Acta Myol 26 1 (2007) 5-10
12. Gamelin E., Gamelin L., Bossi L., and Quasthoff S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 29 5 Suppl 15 (2002) 21-33
13. Adelsberger H., Quasthoff S., Grosskreutz J., et al. The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. Eur J Pharmacol 406 1 (2000) 25-32
14. Grolleau F., Gamelin L., Boisdron-Celle M., et al. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 85 5 (2001) 2293-2297
15. Krishnan A.V., Goldstein D., Friedlander M., and Kiernan M.C. Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve 32 (2005) 51-60
16. Grothey A., and Goldberg R.M. A review of oxaliplatin and its clinical use in colorectal cancer. Expert Opin Pharmacother 5 10 (2004) 2159-2170
17. Cavaletti G., Tredici G., Petruccioli M.G., Dondè E., Tredici P., Marmiroli P., et al. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur J Cancer 37 18 (2001) 2457-2463
18. Screnci D., McKeage M.J., Galettis P., Hambley T.W., Palmer B.D., and Baguley B.C. Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs. Br J Cancer 82 4 (2000) 966-972
19. Adelsberger H., Quasthoff S., Grosskreutz J., et al. Alteration of sodium channel inactivation kinetics on rat sural nerve by the chemotherapeutic agent oxaliplatin. Biol Chem 380S (1999) 123
20. Kann O., and Kovács R. Mitochondria and neuronal activity. Am J Physiol Cell Physiol 292 2 (2007) C641-C657
21. Goodisman J., Hagrman D., Tacka K.A., and Souid A.K. Analysis of cytotoxicities of platinum compounds. Cancer Chemother Pharmacol 57 2 (2006) 257-267
22. National Cancer Institute: Common Toxicity Criteria version 2.0., 1999. Available from : .
23. Oken M.M., Creech R.H., Tormey D.C., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5 (1982) 649-655
24. Ajani J.A., Welch S.R., Raber M.N., et al. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 8 (1990) 147-159
25. Miller A.B., Hoogstraten B., Staquet M., and Winkler A. Reporting results of cancer treatment. Cancer 47 (1981) 207-214
26. Bertheault-Cvitkovic F., Jami A., Ithzaki M., Brummer P.D., Brienza S., Adam R., et al. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 14 11 (1996) 2950-2958
27. Rothenberg M.L., Oza A.M., Bigelow R.H., Berlin J.D., Marshall J.L., Ramanathan R.K., et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 21 11 (2003) 2059-2069
28. Postma T.J., Heimans J.J., Muller M.J., Ossenkoppele G.J., Vermorken J.B., and Aaronson N.K. Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 9 (1998) 739-744
29. Cavaletti G., Bogliun G., Marzorati L., et al. Grading of chemotherapy-induced peripheral neurotoxicity using the total neuropathy scale. Neurology 61 (2003) 1297-1300
30. Cornblath D.R., Chaudhry V., Carter K., et al. Total neuropathy score. Validation and reliability study. Neurology 53 (1999) 1660-1664
31. Cavaletti G., Frigeni B., Lanzani F., Piatti M., Rota S., Briani C., et al. Italian NETox Group. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst 12 3 (2007) 210-215
32. Argyriou AA, Polychronopoulos P, Iconomou G, Koutras A, Makatsoris T, Gerolymos MK, et al. Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer. Acta Oncol doi: 10.1080/02841860701355055.
33. Argyriou A.A., Polychronopoulos P., Koutras A., Iconomou G., Iconomou A., Kalofonos H.P., and Chroni E. Peripheral neuropathy induced by administration of cisplatin and paclitaxel-based chemotherapy. Could it be predicted?. Support Care Cancer 13 8 (2005) 647-651
34. Kemeny N., Garay C.A., Gurtler J., Hochster H., Kennedy P., Benson A., Brandt D.S., et al. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. J Clin Oncol 22 23 (2004) 4753-4761
35. de Gramont A., Figer A., Seymour M., Homerin M., Hmissi A., Cassidy J., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18 16 (2000) 2938-2947
36. Becouarn Y., Ychou M., Ducreux M., Borel C., Bertheault-Cvitkovic F., Seitz J.F., et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J Clin Oncol 16 8 (1998) 2739-2744
37. Diaz-Rubio E., Sastre J., Zaniboni A., Labianca R., Cortes-Funes H., de Braud F., et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol 9 1 (1998) 105-108
38. Machover D., Diaz-Rubio E., de Gramont A., Schilf A., Gastiaburu J.J., Brienza S., et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 7 1 (1996) 95-98
39. Wilson R.H., Lehky T., Thomas R.R., Quinn M.G., Floeter M.K., and Grem J.L. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 20 7 (2002) 1767-1774
40. Lehky T.J., Leonard G.D., Wilson R.H., Grem J.L., and Floeter M.K. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 29 (2004) 387-392
41. Grothey A. Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer 5 Suppl 1 (2005) S38-S46
42. Gornet J.M., Savier E., Lokiec F., Cvitkovic E., Misset J.L., and Goldwasser F. Exacerbation of oxaliplatin neurosensory toxicity following surgery. Ann Oncol 13 8 (2002) 1315-1318
43. Maindrault-Goebel F., Louvet C., Andre T., Carola E., Lotz J.P., Molitor J.L., et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer(FOLFOX6). GERCOR. Eur J Cancer 35 9 (1999) 1338-1342
44. Maindrault-Goebel F., de Gramont A., Louvet C., Andre T., Carola E., Mabro M., et al. High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer 37 8 (2001) 1000-1005
45. Tournigand C., Andre T., Achille E., Lledo G., Flesh M., Mery-Mignard D., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22 2 (2004) 229-237
46. Andre T., Boni C., Mounedji-Boudiaf L., et al. for the multicenter international study of oxaliplatin/5-fluorouracil/leucovorin in the adjuvant treatment of colon cancer (MOSAIC) investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350 23 (2004) 2343-2351
47. Kalofonos H.P., Aravantinos G., Kosmidis P., et al. Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study. Ann Oncol 16 6 (2005) 869-877
48. Graham M.A., Lockwood G.F., Greenslade D., Brienza S., Bayssas M., and Gamelin E. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 6 4 (2000) 1205-1218
49. Schmoll H.J. The role of oxaliplatin in the treatment of advanced metastatic colorectal cancer: prospects and future directions. Semin Oncol 29 5 Suppl 15 (2002) 34-39
50. van Dijk J.G., Lammers G.J., Wintzen A.R., and Molenaar P.C. Repetitive CMAPs: mechanisms of neural and synaptic genesis. Muscle Nerve 19 9 (1996) 1127-1133
51. Taieb S., Trillet-Lenoir V., Rambaud L., Descos L., and Freyer G. Lhermitte sign and urinary retention: atypical presentation of oxaliplatin neurotoxicity in four patients. Cancer 94 9 (2002) 2434-2440
52. Peltier A.C., and Russell J.W. Recent advances in drug-induced neuropathies. Curr Opin Neurol 15 5 (2002) 633-638
53. Extra J.M., Marty M., Brienza S., and Misset J.L. Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 25 (1998) 13-22
54. Grunberg S.M., Sonka S., Stevenson L.L., and Muggia F.M. Progressive paraesthesias after cessation of therapy with very high dose cisplatin. Cancer Chemother Pharmacol 25 (1989) 62-64
55. Choi J., Kong K., Mozaffar T., and Holcombe R.F. Delayed oxaliplatin-associated neurotoxicity following adjuvant chemotherapy for stage III colon cancer. Anti-Cancer Drugs 17 (2006) 103-105
56. White H.S. Comparative anticonvulsivant and mechanistic profile of the established and newer antiepileptic drugs. Epilepsia 40 suppl 5 (1999) S2-S10
57. Wong G.Y., Michalak J.C., Sloan J.A., et al. A phase III double-blinded, placebo controlled randomized trialof gabapentin in patients with chemotherapy-induced peripheral neuropathy: a North Central Cancer Treatment Group Study (abstract). J Clin Oncol 23 Suppl (2005) 8001
58. Guindon J., Walczak J.S., and Beaulieu P. Recent advances in the pharmacological management of pain. Drugs 67 15 (2007) 2121-2133
59. Wasif Saif M., and Hashmi S. Successful amelioration of oxaliplatin-induced hyperexcitability syndrome with the antiepileptic pregabalin in a patient with pancreatic cancer. Cancer Chemother Pharmacol (2007) Epub ahead of print
60. Gamelin L., Boisdron-Celle M., Delva R., et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 10 12 Pt 1 (2004) 4055-4061
61. Santini V. Amifostine: chemotherapeutic and radiotherapeutic protective effects. Expert Opin Pharmacother 2 3 (2001) 479-489
62. Penz M., Kornek G.V., Raderer M., et al. Subcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy. Ann Oncol 12 3 (2001) 421-422
63. Reynolds A., Laurie C., Lee Mosley R., and Gendelman H.E. Oxidative stress and the pathogenesis of neurodegenerative disorders. Int Rev Neurobiol 82 (2007) 297-325
64. Holmes J., Stanko J., Varchenko M., Ding H., Madden V.J., Bagnell C.R., et al. Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model. Toxicol Sci 46 2 (1998) 342-351
65. Cascinu S., Catalano V., Cordella L., Labianca R., Giordani P., Baldelli A.M., et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 20 16 (2002) 3478-3483
66. Wang W.S., Lin J.K., Lin T.C., Chen W.S., Jiang J.K., Wang H.S., et al. Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. Oncologist 12 3 (2007) 312-319
67. Gedlicka C., Scheithauer W., Schull B., et al. Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid. J Clin Oncol 20 15 (2002) 3359-3361
68. Hochster H.S., Grothey A., and Childs B.H. Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Oncol 25 25 (2007) 4028-4029
69. Doraiswamy P.M., and Xiong G.L. Pharmacological strategies for the prevention of Alzheimer's disease. Expert Opin Pharmacother 7 1 (2006) 1-10
70. Susman E. Xaliproden lessens oxaliplatin-mediated neuropathy. Lancet Oncol 7 4 (2006) 288
71. Gibson T.B., Ranganathan A., and D'Orazio A. American society of clinical oncology. Highlights From: the 2006 American society of clinical oncology gastrointestinal cancers symposium San Francisco, CA, January 2006. Clin Colorectal Cancer 5 6 (2006) 398-402
72. McCleane G. Pharmacological management of neuropathic pain. CNS Drugs 17 14 (2003) 1031-1043
73. Eckel F., Schmelz R., Adelsberger H., Erdmann J., Quasthoff S., and Lersch C. Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study. Dtsch Med Wochenschr 127 3 (2002) 78-82
74. von Delius S., Eckel F., Wagenpfeil S., Mayr M., Stock K., Kullmann F., et al. Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: final results of a randomised, controlled, multicenter phase II study. Invest New Drugs 25 2 (2007) 173-180
75. Mariani G, Garrone O, Granetto C, Numico G, LaCiura P, Grecchi G, et al. Oxaliplatin-induced neuropathy: could gabapentin be the answer? (abstract 2397). Proc Am Soc Clin Oncol 2000; 19:609a.
76. Mitchell P.L., Goldstein D., Michael M., Beale P., Friedlander M., Zalcberg J., et al. Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity. Clin Colorectal Cancer 6 2 (2006) 146-151
77. Eisenberg E., River Y., Shifrin A., and Krivoy N. Antiepileptic drugs in the treatment of neuropathic pain. Drugs 67 9 (2007) 1265-1289
78. Durand J.P., Alexandre J., Guillevin L., et al. Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathy. Anticancer Drugs 16 5 (2005) 587-591
79. Schmidt D., and Elger C.E. What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs?. Epilepsy Behav 5 5 (2004) 627-635
80. Argyriou A.A., Chroni E., Polychronopoulos P., et al. Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy. Neurology 67 12 (2006) 2253-2255
81. Petrioli R., Paolelli L., Marsili S., Civitelli S., Francini E., Cioppa T., et al. FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer. Oncology 70 5 (2006) 345-350
82. Tournigand C., Cervantes A., Figer A., Lledo G., Flesch M., Buyse M., et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol 24 3 (2006) 394-400
83. Rosa D.D., Ismael G.F., de Azambuja E., Braga S., Cardoso F., and Bleiberg H. OPTIMOX1 in advanced colorectal cancer: lack of evidence for a stop-and-go strategy. J Clin Oncol 24 32 (2006) 5176-5177
84. André T., Tournigand C., Mineur L., Fellague-Chebra R., Flesch M., et al. Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study. Ann Oncol 18 1 (2007) 77-81